Abstract:The observation by Colombo and colleagues 1 that dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 antagonist, offers optimal antithrombotic protection following intracoronary stent implantation catalyzed the widespread adoption of intracoronary stents. Historically, stent thrombosis, a catastrophic event, was a concern primarily in the immediate aftermath of stent placement. However, the observation of stent thromboses occurring beyond 30 days in patients receiving first-generation, drug-eluting stents underscored the persistent nature of this risk. Consequently, the ideal DAPT duration has become the focal point of innumerable clinical trials and meta-analyses, even as stent thrombosis has substantially declined with modern stent platforms and intravascular imaging techniques. The challenge lies in balancing the ischemic risk associated with shorter DAPT duration against the bleeding risk entailed by extended therapy. While intuitively one might expect a bleeding event to be less catastrophic than stent thrombosis or myocardial infarction, studies 2 have shown otherwise. This dilemma is particularly accentuated in older adults, whose complex health profiles amplify their susceptibility to both bleeding and ischemic complications. Park and colleagues 3 present a network meta-analysis (NMA) evaluating various DAPT durations following percutaneous coronary interventions (PCI) in older adults. Among 14 trials, including 19 102 participants aged 65 years or older, they found no significant differences in major adverse cardiovascular events (MACE) or net adverse clinical events (NACE), as defined variably in each trial, across 1-, 3-, 6-, or 12-month DAPT. 3 The study showed that short-term DAPT strategies (ie, 3- vs 6-month DAPT, 3- vs 12-month DAPT, and 1- vs 6-month DAPT) were associated with a significant reduction in bleeding risk, suggesting that short-term DAPT may offer a safer option for older adults without compromising efficacy against MACE or NACE. 3 While evaluating the ischemic and bleeding risk is fundamentally a bivariate process, NACE, which includes bleeding and ischemic events, was introduced as a unidimensional metric to quantify the overall risk-benefit profile of antithrombotic therapies. In this NMA, 3 given that 1- to 3-month DAPT compared with 6- to 12-month DAPT was associated with reduced bleeding risk without increasing ischemic risk, one would anticipate a corresponding reduction in NACE rather than a null effect. Additionally, the observation that 1-month compared with 6-month DAPT, but not 12-month DAPT, reduced bleeding prompts scrutiny of study design and evidence before clinical application. Using indirect evidence in an NMA requires the assumption that compared trials share similarities in patient characteristics, treatment protocol, and outcome measures. However, verifying this assumption is complicated by trial-level heterogeneity, including differences in antiplatelet therapies after DAPT deescalation, baseline risks for bleeding and ischemic events, and outcome definitions. For instance, the SMART-CHOICE trial 4 indicated that clopidogrel after 3-month DAPT in a broad patient population was effective in reducing bleeding without compromising MACE. Conversely, the TWILIGHT trial 5 found that ticagrelor monotherapy following 3-month DAPT vs 12-month DAPT decreased bleeding without elevating ischemic risk in high-risk patients. The diversity in antiplatelet therapy among trials, involving 3 different P2Y12 antagonists and different doses of aspirin, further complicates the analysis. 3 Moreover, several additional issues pose challenges when translating these findings into clinical practice. For instance, aligning events of comparable clinical significance on both sides of the calculus is imperative for a precise assessment of the risk-benefit ratio. The definitions of NACE and MACE in each trial incorporated events of varying clinical significance, ranging from all-cause mortality to less critical events like target vessel revascularization. 3 Additionally, only 5 trials included stent thrombosis in composite outcomes, and inconsistencies exist in classifying bleeding risk across trials. The distinct relative risk reductions offered by different DAPT regimens for various end points further emphasize the necessity of analyzing treatment effects on individual end points. Nonetheless, acknowledging these limitations, what does this study 3 add to the evidence? Consistent with recent evidence in other populations, this NMA 3 supports the notion that short-term DAPT is likely the ideal strategy to minimize the bleeding risk without compromising the protection against ischemic events in older adults. However, a universal DAPT duration and selection approach may not apply to all patient scenarios. Lim -Abstract Truncated-

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High …

Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy after Coronary Stenting.

Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes

Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack

Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.

Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT

Incidence and outcome of gastrointestinal bleeding in patients receiving aspirin with or without clopidogrel over 10 years- An observational study

Bleeding after percutaneous coronary intervention and selection of candidates for long-term dual antithrombotic treatment

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how

Optimizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis

Comparison of the Efficacy of Dual Antiplatelet Treatment at Different Treatment Times in Patients with High Bleeding Risk after PCI: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Long-term Dual Antiplatelet-Induced Intestinal Injury Resulting in Translocation of Intestinal Bacteria into Blood Circulation Increased the Incidence of Adverse Events after PCI in Patients with Coronary Artery Disease.

Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention

The impact of dual antiplatelet therapy administration on the risk of bleeding complications during coronary artery bypass surgery

Extended Clopidogrel Monotherapy Vs DAPT in Patients with Acute Coronary Syndromes at High Ischemic and Bleeding Risk the OPT-BIRISK Randomized Clinical Trial

Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis

Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs

Ticagrelor with or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients with Concomitant Peripheral Artery Disease: a Subgroup Analysis of the TWILIGHT Randomized Clinical Trial

Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk

Impact Of 6-Versus 12-Month Dual Antiplatelet Therapy On Clinical Prognosis In Patients With High Bleeding Risk: Insights From The 4-Year Results Of The I Love It 2 Study